Moreover, EGFR and K-Ras mutations are mutually exclusive in NSCLC with the emergence of K-Ras mutations associated with resistance to EGFR-targeted cancer therapies (Diaz et al, 2012; Misale et al, 2012). Here, KRAS is linked to non-small cell lung carcinoma.